Alliancebernstein L.P. Acquires Shares of 12,700 WAVE Life Sciences Ltd. (WVE)
Alliancebernstein L.P. acquired a new stake in WAVE Life Sciences Ltd. (NASDAQ:WVE) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 12,700 shares of the company’s stock, valued at approximately $236,000.
Several other hedge funds and other institutional investors have also bought and sold shares of WVE. Bank of New York Mellon Corp raised its holdings in shares of WAVE Life Sciences by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 31,350 shares of the company’s stock valued at $862,000 after purchasing an additional 279 shares during the last quarter. American International Group Inc. increased its holdings in WAVE Life Sciences by 7.1% during the first quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the last quarter. Geode Capital Management LLC increased its holdings in WAVE Life Sciences by 4.6% during the first quarter. Geode Capital Management LLC now owns 76,478 shares of the company’s stock worth $2,103,000 after buying an additional 3,397 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in WAVE Life Sciences by 6.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 30,707 shares of the company’s stock worth $845,000 after buying an additional 1,881 shares during the last quarter. Finally, Strs Ohio increased its holdings in WAVE Life Sciences by 6.3% during the second quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $221,000 after buying an additional 700 shares during the last quarter. Institutional investors own 69.79% of the company’s stock.
In related news, Director Masaharu Tanaka sold 20,747 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $24.21, for a total value of $502,284.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 53.00% of the stock is owned by insiders.
WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/alliancebernstein-l-p-acquires-shares-of-12700-wave-life-sciences-ltd-wve/1699318.html.
A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. BidaskClub raised shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Mizuho set a $34.00 price objective on shares of WAVE Life Sciences and gave the stock a “buy” rating in a research report on Friday, August 18th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $40.00 price objective (down from $42.00) on shares of WAVE Life Sciences in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. WAVE Life Sciences presently has an average rating of “Hold” and an average price target of $38.75.
Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) opened at $22.80 on Monday. WAVE Life Sciences Ltd. has a 52-week low of $15.15 and a 52-week high of $40.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.94 and a current ratio of 12.94.
WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.97) by $0.03. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.77 million. WAVE Life Sciences had a negative net margin of 3,338.68% and a negative return on equity of 61.43%. equities analysts forecast that WAVE Life Sciences Ltd. will post -3.75 EPS for the current fiscal year.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.